pith. sign in

arxiv: 1907.07713 · v1 · pith:2I724E7Dnew · submitted 2019-07-17 · 📡 eess.IV · cs.LG· q-bio.QM· stat.ML

An AI-Augmented Lesion Detection Framework For Liver Metastases With Model Interpretability

Xin J. Hunt , Ralph Abbey , Ricky Tharrington , Joost Huiskens , Nina Wesdorp This is my paper

Pith reviewed 2026-05-24 19:56 UTC · model grok-4.3

classification 📡 eess.IV cs.LGq-bio.QMstat.ML
keywords liver metastasesAI-augmented frameworkmodel interpretabilitylesion detectionRECISTcolorectal cancerinteractive AI
0
0 comments X

The pith

An interactive AI system with model interpretability assists clinicians in assessing liver metastases.

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The paper proposes a framework for using AI to help detect and measure liver lesions from colorectal cancer metastases. Current RECIST assessments are manual, time-consuming, and subjective. The framework makes the AI interactive and provides explanations for its outputs to improve clinician trust and adoption in practice.

Core claim

The authors present a framework for an AI-augmented system in which an interactive AI assists clinicians in metastasis assessment by detecting lesions and providing model interpretability to explain the reasoning of the underlying models.

What carries the argument

An interactive AI-augmented framework incorporating model interpretability for lesion detection in liver metastases.

If this is right

  • Clinicians receive assistance in the time-consuming task of measuring tumor sizes.
  • Explanations of AI reasoning address issues of trust in clinical settings.
  • The system can be integrated into workflows for metastasis assessment without replacing clinician judgment.

Where Pith is reading between the lines

These are editorial extensions of the paper, not claims the author makes directly.

  • Such a system could reduce variability in RECIST measurements across different clinicians.
  • Future work might involve validating the framework on larger clinical datasets to confirm its utility.
  • Integration with existing medical imaging tools could enhance its practicality.

Load-bearing premise

That providing model interpretability will sufficiently overcome trust and implementation barriers for AI in clinical metastasis assessment.

What would settle it

A clinical study where adding interpretability does not increase clinician trust or usage rates of the AI system compared to a non-interpretable version.

Figures

Figures reproduced from arXiv: 1907.07713 by Joost Huiskens, Nina Wesdorp, Ralph Abbey, Ricky Tharrington, Xin J. Hunt.

Figure 1
Figure 1. Figure 1: Flow chart of the proposed system [PITH_FULL_IMAGE:figures/full_fig_p002_1.png] view at source ↗
Figure 2
Figure 2. Figure 2: A sample report. The clinician can confirm or re [PITH_FULL_IMAGE:figures/full_fig_p004_2.png] view at source ↗
read the original abstract

Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer-related deaths worldwide. Most CRC deaths are the result of progression of metastases. The assessment of metastases is done using the RECIST criterion, which is time consuming and subjective, as clinicians need to manually measure anatomical tumor sizes. AI has many successes in image object detection, but often suffers because the models used are not interpretable, leading to issues in trust and implementation in the clinical setting. We propose a framework for an AI-augmented system in which an interactive AI system assists clinicians in the metastasis assessment. We include model interpretability to give explanations of the reasoning of the underlying models.

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, simulated authors' rebuttal, and a circularity audit. Tearing a paper down is the easy half of reading it; the pith above is the substance, this is the friction.

Referee Report

2 major / 1 minor

Summary. The manuscript proposes a high-level AI-augmented interactive framework to assist clinicians in RECIST-based assessment of liver metastases from colorectal cancer. It identifies subjectivity in manual measurement and lack of interpretability in existing AI detectors as barriers to clinical adoption, and claims that adding model interpretability will produce explanations that improve trust and implementation.

Significance. A validated interactive system with interpretable outputs could reduce assessment time and inter-observer variability in metastasis evaluation. The significance cannot be assessed from the current text because the manuscript supplies neither an implemented system nor any empirical test of whether the interpretability component changes clinician behavior, confidence, or adoption relative to a black-box baseline.

major comments (2)
  1. [Abstract] Abstract (final sentence) and overall manuscript: the claim that model interpretability will address trust and implementation barriers is presented as a central motivation, yet no clinician study, trust metric, adoption measure, or comparison against a non-interpretable baseline is described or planned.
  2. Entire manuscript: no methods, data, results, evaluation protocol, or even a concrete description of the detection architecture, RECIST integration, or interpretability technique (e.g., saliency maps, concept activation vectors) are provided, rendering the feasibility of the proposed framework unassessable.
minor comments (1)
  1. The text remains at the level of a system sketch; if the authors intend a conceptual paper, explicit statements of the framework's scope and the precise open questions it leaves for future work would improve clarity.

Simulated Author's Rebuttal

2 responses · 0 unresolved

We thank the referee for the review. The manuscript describes a high-level conceptual framework for an AI-augmented interactive system incorporating model interpretability to support RECIST assessment of liver metastases. It does not present an implemented system or empirical validation. We respond to each major comment below.

read point-by-point responses

  1. Referee: [Abstract] Abstract (final sentence) and overall manuscript: the claim that model interpretability will address trust and implementation barriers is presented as a central motivation, yet no clinician study, trust metric, adoption measure, or comparison against a non-interpretable baseline is described or planned.

    Authors: The motivation draws on established literature regarding barriers to clinical adoption of black-box AI models. The manuscript is a framework proposal and does not claim to have conducted or planned a specific clinician study, trust metric, or baseline comparison. We will revise the abstract and introduction to state explicitly that improved trust and implementation are hypothesized outcomes that would require future empirical validation. revision: partial

  2. Referee: Entire manuscript: no methods, data, results, evaluation protocol, or even a concrete description of the detection architecture, RECIST integration, or interpretability technique (e.g., saliency maps, concept activation vectors) are provided, rendering the feasibility of the proposed framework unassessable.

    Authors: The manuscript intentionally focuses on the overall framework concept at a high level rather than providing implementation details, data, or evaluation protocols, as it is not an empirical study. We acknowledge that greater specificity on components such as detection architecture and interpretability methods would aid assessment and will add high-level descriptions of example techniques (e.g., saliency maps) in revision. revision: partial

Circularity Check

0 steps flagged

No derivation chain or fitted quantities present

full rationale

The manuscript is a high-level proposal for an interactive AI framework incorporating model interpretability for liver metastasis assessment under RECIST. No equations, parameters, predictions, or derivations appear in the provided text or abstract. The central claim is architectural and descriptive rather than a mathematical reduction; the assumption that interpretability improves trust is an untested premise but does not constitute circularity by construction, self-definition, or self-citation load-bearing. The paper is self-contained as a system description with no load-bearing steps that reduce to their own inputs.

Axiom & Free-Parameter Ledger

0 free parameters · 0 axioms · 0 invented entities

No mathematical derivations, fitted parameters, or new entities are introduced; the document is a system proposal based on existing AI and clinical practices.

pith-pipeline@v0.9.0 · 5666 in / 954 out tokens · 13652 ms · 2026-05-24T19:56:14.818921+00:00 · methodology

discussion (0)

Sign in with ORCID, Apple, or X to comment. Anyone can read and Pith papers without signing in.

Reference graph

Works this paper leans on

33 extracted references · 33 canonical work pages · 2 internal anchors

  1. [1]

    Eddie K Abdalla, Rene Adam, Anton J Bilchik, Daniel Jaeck, Jean-Nicolas Vauthey, and David Mahvi. 2006. Improving resectability of hepatic colorectal metastases: expert consensus statement. Annals of surgical oncology 13, 10 (2006), 1271–1280

    work page 2006

  2. [2]

    René Adam, Valérie Delvart, Gérard Pascal, Adrian Valeanu, Denis Castaing, Daniel Azoulay, Sylvie Giacchetti, Bernard Paule, Francis Kunstlinger, Odile Ghémard, et al. 2004. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Annals of surgery 240, 4 (2004), 644

    work page 2004

  3. [3]

    Elaine Angelino, Nicholas Larus-Stone, Daniel Alabi, Margo Seltzer, and Cynthia Rudin. 2017. Certifiably optimal rule lists for categorical data. In Proceedings of the 23rd ACM SIGKDD Conference of Knowledge, Discovery, and Data Mining (KDD)

    work page 2017

  4. [4]

    J-H Angelsen, A Horn, H Sorbye, GE Eide, IM Løes, and A Viste. 2017. Population- based study on resection rates and survival in patients with colorectal liver metastasis in Norway. British Journal of Surgery 104, 5 (2017), 580–589

    work page 2017

  5. [5]

    Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, and Ahmedin Jemal. 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 68, 6 (2018), 394–424

    work page 2018

  6. [6]

    MV d Eynde and Alain Hendlisz. 2009. Treatment of colorectal liver metastases: a review. Reviews on recent clinical trials 4, 1 (2009), 56–62

    work page 2009

  7. [7]

    Jannemarie AM de Ridder, Eric P van der Stok, Leonie J Mekenkamp, Bastiaan Wiering, Miriam Koopman, Cornelis JA Punt, Cornelis Verhoef, and H Johannes

    work page

  8. [8]

    European Journal of Cancer 59 (2016), 13–21

    Management of liver metastases in colorectal cancer patients: a retrospec- tive case-control study of systemic therapy versus liver resection. European Journal of Cancer 59 (2016), 13–21

    work page 2016

  9. [9]

    Matteo Donadon, Dario Ribero, Gareth Morris-Stiff, Eddie K Abdalla, and Jean- Nicolas Vauthey. 2007. New paradigm in the management of liver-only metastases from colorectal cancer. Gastrointestinal cancer research: GCR 1, 1 (2007), 20

    work page 2007

  10. [10]

    Keith J Dreyer and J Raymond Geis. 2017. When machines think: radiologyâĂŹs next frontier. Radiology 285, 3 (2017), 713–718

    work page 2017

  11. [11]

    Elizabeth A Eisenhauer, Patrick Therasse, Jan Bogaerts, Lawrence H Schwartz, D Sargent, Robert Ford, Janet Dancey, S Arbuck, Steve Gwyther, Margaret Mooney, et al. 2009. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European journal of cancer 45, 2 (2009), 228–247

    work page 2009

  12. [12]

    Charlie A Hamm, Clinton J Wang, Lynn J Savic, Marc Ferrante, Isabel Schobert, Todd Schlachter, MingDe Lin, James S Duncan, Jeffrey C Weinreb, Julius Chapiro, et al. 2019. Deep learning for liver tumor diagnosis part I: development of a convolutional neural network classifier for multi-phasic MRI. European radiology (2019), 1–10

    work page 2019

  13. [13]

    Jianxing He, Sally L Baxter, Jie Xu, Jiming Xu, Xingtao Zhou, and Kang Zhang

    work page

  14. [14]

    Nature medicine 25, 1 (2019), 30

    The practical implementation of artificial intelligence technologies in medicine. Nature medicine 25, 1 (2019), 30

    work page 2019

  15. [15]

    Jonathan Huang, Vivek Rathod, Chen Sun, Menglong Zhu, Anoop Korattikara, Alireza Fathi, Ian Fischer, Zbigniew Wojna, Yang Song, Sergio Guadarrama, et al

    work page

  16. [16]

    In Proceedings of the IEEE conference on computer vision and pattern recognition

    Speed/accuracy trade-offs for modern convolutional object detectors. In Proceedings of the IEEE conference on computer vision and pattern recognition . 7310–7311

    work page

  17. [17]

    Joost Huiskens, Thomas M van Gulik, Krijn P van Lienden, Marc RW Engelbrecht, Gerrit A Meijer, Nicole CT van Grieken, Jonne Schriek, Astrid Keijser, Linda Mol, I Quintus Molenaar, et al. 2015. Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the...

    work page 2015

  18. [18]

    Yin Lou, Rich Caruana, Johannes Gehrke, and Giles Hooker. 2013. Accurate intelligible models with pairwise interactions. In Proceedings of the 19th ACM SIGKDD international conference on Knowledge discovery and data mining . ACM, 623–631

    work page 2013

  19. [19]

    Scott M Lundberg and Su-In Lee. 2017. A unified approach to interpreting model predictions. In Advances in Neural Information Processing Systems . 4765–4774

    work page 2017

  20. [20]

    Anum Masood, Bin Sheng, Ping Li, Xuhong Hou, Xiaoer Wei, Jing Qin, and Dagan Feng. 2018. Computer-assisted decision support system in pulmonary cancer detection and stage classification on CT images. Journal of biomedical informatics 79 (2018), 117–128

    work page 2018

  21. [21]

    Jeffrey A Meyerhardt and Robert J Mayer. 2005. Systemic therapy for colorectal cancer. New England Journal of Medicine 352, 5 (2005), 476–487

    work page 2005

  22. [22]

    Grégoire Montavon, Wojciech Samek, and Klaus-Robert Müller. 2018. Methods for interpreting and understanding deep neural networks. Digital Signal Processing 73 (2018), 1–15

    work page 2018

  23. [23]

    Agneta Norén, HG Eriksson, and LI Olsson. 2016. Selection for surgery and survival of synchronous colorectal liver metastases; a nationwide study.European journal of cancer 53 (2016), 105–114

    work page 2016

  24. [24]

    National Working Group on Gastrointestinal Tumors. 2004. Colorectal carcinoma national guideline 2014. https://www.oncoline.nl/colorectaalcarcinoom

    work page 2004

  25. [25]

    Graeme J Poston, Joan Figueras, Felice Giuliante, Gennaro Nuzzo, Alberto F Sobrero, Jean-Francois Gigot, Bernard Nordlinger, Rene Adam, Thomas Gruen- berger, Michael A Choti, et al. 2008. Urgent need for a new staging system in advanced colorectal cancer. Journal of Clinical Oncology 26, 29 (2008), 4828–4833

    work page 2008

  26. [26]

    Marco Tulio Ribeiro, Sameer Singh, and Carlos Guestrin. 2016. Why should i trust you?: Explaining the predictions of any classifier. In Proceedings of the 22nd ACM SIGKDD international conference on knowledge discovery and data mining . ACM, 1135–1144

    work page 2016

  27. [27]

    Marco Tulio Ribeiro, Sameer Singh, and Carlos Guestrin. 2018. Anchors: High- precision model-agnostic explanations. In AAAI Conference on Artificial Intelli- gence

    work page 2018

  28. [28]

    Wojciech Samek, Thomas Wiegand, and Klaus-Robert Müller. 2017. Explainable artificial intelligence: Understanding, visualizing and interpreting deep learning models. arXiv preprint arXiv:1708.08296 (2017)

    work page internal anchor Pith review Pith/arXiv arXiv 2017

  29. [29]

    Erik Strumbelj and Igor Kononenko. 2010. An Efficient Explanation of Individual Classifications Using Game Theory. J. Mach. Learn. Res. 11 (March 2010), 1–18. http://dl.acm.org/citation.cfm?id=1756006.1756007

    work page arXiv 2010

  30. [30]

    Berk Ustun and Cynthia Rudin. 2016. Learning Optimized Risk Scores on Large- Scale Datasets. arXiv preprint arXiv:1610.00168 (2016)

    work page arXiv 2016

  31. [31]

    Dayong Wang, Aditya Khosla, Rishab Gargeya, Humayun Irshad, and Andrew H Beck. 2016. Deep learning for identifying metastatic breast cancer. arXiv preprint arXiv:1606.05718 (2016)

    work page internal anchor Pith review Pith/arXiv arXiv 2016

  32. [32]

    Dennis A Wicherts, Robbert J de Haas, and René Adam. 2007. Bringing un- resectable liver disease to resection with curative intent. European Journal of Surgical Oncology (EJSO) 33 (2007), S42–S51

    work page 2007

  33. [33]

    Soon Ho Yoon, Kyung Won Kim, Jin Mo Goo, Dong-Wan Kim, and Seokyung Hahn. 2016. Observer variability in RECIST-based tumour burden measurements: a meta-analysis. European journal of cancer 53 (2016), 5–15

    work page 2016